FIRAZYR 10 MG
ICATIBANT (ICATIBANT ACETATE) : 10 MG · DIN 02425696 · TAKEDA CANADA INC
Health Canada status: MARKETED
What is FIRAZYR?
FIRAZYR 10 MG contains ICATIBANT (ICATIBANT ACETATE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02425696, held by TAKEDA CANADA INC, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 21-Jul-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is FIRAZYR used for?
Treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older with C1-esterase inhibitor deficiency. (Max 200 chars)
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02425696 |
|---|---|
| Brand name | FIRAZYR |
| Generic / active ingredient | ICATIBANT (ICATIBANT ACETATE) : 10 MG |
| Manufacturer | TAKEDA CANADA INC |
| Strength | 10 MG |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | B06AC02 ICATIBANT |
| AHFS class | 92:32.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 21-Jul-2021 |
| Original market date | 2014-07-14 00:00:00 |
How is it administered?
Adults: 30 mg SC; max 3 doses/24h. Pediatrics (2-17y): Weight-based dosing (10-30 mg). Administer by slow SC injection in the abdominal area over at least 30 seconds.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (section 11 header present but content truncated), though typically room temperature for this product.
How is it supplied?
Carton includes one 3 mL glass prefilled syringe with a 25 G needle. Patient self-administration kits available through OnePath program.
Contraindications
Hypersensitivity to icatibant or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Laryngeal attacks require immediate medical attention. May aggravate cardiac ischemia. Caution against driving/operating machinery if fatigue or dizziness occurs.
Is ICATIBANT in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by JAMP PHARMA CORPORATION, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code B06AC02 ICATIBANT. 2 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ICATIBANT INJECTION | 10 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02547562 |
| ICATIBANT INJECTION | 10 MG | SOLUTION | JUNO PHARMACEUTICALS CORP. | CANCELLED PRE MARKET | DIN 02523337 |
| ICATIBANT INJECTION | 30 MG / 3 ML | SOLUTION | ACCORD HEALTHCARE INC | CANCELLED PRE MARKET | DIN 02516608 |
| MINT-ICATIBANT | 10 MG | SOLUTION | MINT PHARMACEUTICALS INC | APPROVED | DIN 02524619 |
| TEVA-ICATIBANT | 10 MG | SOLUTION | TEVA CANADA LIMITED | CANCELLED PRE MARKET | DIN 02513773 |
Who else supplies ICATIBANT worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ICATIBANT appears in 47 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.